AxSpA Treatment Intensification in Practice Linked With Higher ASDAS Cutoff Than Recommended

Retrieved on: 2024-06-22 12:08:09

Tags for this article:

Click the tags to see associated articles and topics

AxSpA Treatment Intensification in Practice Linked With Higher ASDAS Cutoff Than Recommended. View article details on hiswai:

Excerpt

At the end of 2023, the FDA approved 2 innovative gene therapies, exa-cel and lovo-cel, offering potential cures for sickle cell disease (SCD).

Article found on: www.ajmc.com